Exactech, Inc. (NASDAQ:EXAC) was upgraded by equities research analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Friday.
Other equities analysts have also issued reports about the company. Gabelli reissued a “buy” rating on shares of Exactech in a report on Monday, July 31st. TheStreet raised Exactech from a “c+” rating to a “b” rating in a report on Tuesday, April 25th. Finally, Zacks Investment Research raised Exactech from a “sell” rating to a “hold” rating in a report on Tuesday, April 25th.
Exactech (NASDAQ:EXAC) traded up 0.51% during mid-day trading on Friday, reaching $29.65. The company had a trading volume of 12,104 shares. Exactech has a 12-month low of $22.20 and a 12-month high of $31.90. The company has a market capitalization of $425.42 million, a price-to-earnings ratio of 570.19 and a beta of 1.02. The stock has a 50-day moving average of $29.42 and a 200 day moving average of $28.07.
Exactech (NASDAQ:EXAC) last announced its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.33 earnings per share for the quarter, meeting the consensus estimate of $0.33. Exactech had a return on equity of 7.39% and a net margin of 0.30%. The business had revenue of $67.30 million during the quarter, compared to analyst estimates of $67.75 million. During the same period in the prior year, the company earned $0.31 earnings per share. Exactech’s revenue was up 1.8% compared to the same quarter last year. On average, analysts expect that Exactech will post $1.29 EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Exactech, Inc. (EXAC) Stock Rating Upgraded by BidaskClub” was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://www.com-unik.info/2017/08/18/exactech-inc-exac-stock-rating-upgraded-by-bidaskclub.html.
In other news, Director Fern Watts sold 1,013 shares of the firm’s stock in a transaction on Tuesday, August 8th. The stock was sold at an average price of $29.04, for a total value of $29,417.52. Following the completion of the transaction, the director now directly owns 4,727 shares of the company’s stock, valued at $137,272.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Joel C. Phillips sold 7,610 shares of the firm’s stock in a transaction on Tuesday, May 23rd. The stock was sold at an average price of $30.71, for a total value of $233,703.10. Following the completion of the transaction, the chief financial officer now directly owns 99,907 shares of the company’s stock, valued at $3,068,143.97. The disclosure for this sale can be found here. Over the last three months, insiders have sold 10,358 shares of company stock valued at $314,311. 28.30% of the stock is owned by corporate insiders.
Several institutional investors have recently bought and sold shares of the company. The Manufacturers Life Insurance Company raised its position in Exactech by 3.2% in the second quarter. The Manufacturers Life Insurance Company now owns 9,323 shares of the medical equipment provider’s stock worth $278,000 after buying an additional 289 shares during the last quarter. State Street Corp raised its position in Exactech by 7.5% in the second quarter. State Street Corp now owns 207,721 shares of the medical equipment provider’s stock worth $6,192,000 after buying an additional 14,537 shares during the last quarter. Numeric Investors LLC raised its position in Exactech by 4.4% in the second quarter. Numeric Investors LLC now owns 30,643 shares of the medical equipment provider’s stock worth $913,000 after buying an additional 1,300 shares during the last quarter. Voya Investment Management LLC bought a new position in Exactech during the second quarter worth approximately $243,000. Finally, OxFORD Asset Management LLP raised its position in Exactech by 17.8% in the second quarter. OxFORD Asset Management LLP now owns 59,972 shares of the medical equipment provider’s stock worth $1,787,000 after buying an additional 9,082 shares during the last quarter. 64.05% of the stock is owned by hedge funds and other institutional investors.
Exactech Company Profile
Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines.
What are top analysts saying about Exactech Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Exactech Inc. and related companies.